UnknownPhase 3

Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome

China400 participantsStarted 2017-04-10

Plain-language summary

Preterm and very preterm infants are at risk of developing encephalopathy of prematurity and long-term neurodevelopmental delay. Magnetic resonance imaging (MRI) allows the characterization of specific features of encephalopathy of prematurity, including structural changes of brain white matter and gray matter. This study wants to investigate important evidence that early repeated high-dose rhEPO(5250 IU/kg) treatment improves long-term neurological outcomes in very preterm infants and without obvious adverse effects.

Who can participate

Age range3 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * premature infants who admitted to the neonatal intensive care unit(NICU) Within 72 hours after birth, gestational ages younger than 32 weeks, birth weight less than 1500 gram, informed consent was obtained from the infants' parents or guardians Exclusion Criteria: * born with anemia, polycythemia, hemolysis and other hematological diseases * hypertension, * convulsions, * a genetically defined syndrome * a severe congenital malformation adversely affecting life expectancy or neurodevelopment * severe intraventricular hemorrhage * thrombosis disease * other fatal diseases or which can seriously affect the prognosis

What they're measuring

Neurodevelopmental outcome

Timeframe: corrected age of 18 months

Trial details

NCT IDNCT03110341

SponsorFirst Affiliated Hospital Xi'an Jiaotong University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

Contact for this trial

Xihui Zhou, Doctor

+8618991232230 zhouxih@xjtu.edu.cn

View on ClinicalTrials.gov More Premature Infants trials